The effect of 18F-FDG PET/CT findings on prognosis in patients with diffuse large B cell lymphoma

Seda Yılmaz; Mustafa Erol

Makale detayları

The effect of 18F-FDG PET/CT findings on prognosis in patients with diffuse large B cell lymphoma

Yazarlar:

Seda Yılmaz | Mustafa Erol

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Hematoloji

Dergi:

Journal of Health Sciences and Medicine Vol.6 Issue 6, pp.1337-1341

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001303060

pISSN:

2636-8579

Anahtar kelimeler:

Özet:

 Aims: 18F-fluorodeoxyglucose 18F-FDG positron emission tomographycomputed tomography PETCT, plays an important role in both staging at the time of diagnosis and follow-up of treatment response in lymphoma. Our aim was to investigate the effect of different quantitative metabolic parameters, which are not used in routine practice, on treatment response and overall survival OS in patients with diffuse large B-cell lymphoma. Methods: A total of 26 patients were included in our retrospective cohort study. Deauville 5-point scale 5-PS, and cut-off values for changes in maximum standardized uptake value SUVmax, peak SUV SUVpeak, metabolic tumor volume MTV2.5-41- PERCIST -aort and total lesion glycolysis index TLG 2.5-41- PERCIST-aort effect of metabolic parameters on treatment response and OS was investigated. Results: Metabolic parameters did not predict treatment response, while TLGPERCIST p0.034, TLGAORT p0.040, MTV41 p0.040 and TLG41 p0.034 parameters were statistically significant for OS. Median OS months was statistically significant in TLGPERCIST groups p0.047. While the median OS months in the TLGPERCIST 4411.90 group was inaccessible, the median OS in the 4411.90 group was 32.00 95CI: 0.00-87.43 months. Median OS months was statistically significant in MTV41 groups p0.047. While median OS months was inaccessible in the MTV41376.10 group, median OS in the 376.10 group was 32.00 95CI: 0.00-87.43 months. Conclusion: The MTV41 and TLGPERCIST appear to be the best parameter to predict OS in patients diagnosed with DLBCL by 18F-FDG PETCT.

 Aims: 18F-fluorodeoxyglucose 18F-FDG positron emission tomographycomputed tomography PETCT, plays an important role in both staging at the time of diagnosis and follow-up of treatment response in lymphoma. Our aim was to investigate the effect of different quantitative metabolic parameters, which are not used in routine practice, on treatment response and overall survival OS in patients with diffuse large B-cell lymphoma. Methods: A total of 26 patients were included in our retrospective cohort study. Deauville 5-point scale 5-PS, and cut-off values for changes in maximum standardized uptake value SUVmax, peak SUV SUVpeak, metabolic tumor volume MTV2.5-41- PERCIST -aort and total lesion glycolysis index TLG 2.5-41- PERCIST-aort effect of metabolic parameters on treatment response and OS was investigated. Results: Metabolic parameters did not predict treatment response, while TLGPERCIST p0.034, TLGAORT p0.040, MTV41 p0.040 and TLG41 p0.034 parameters were statistically significant for OS. Median OS months was statistically significant in TLGPERCIST groups p0.047. While the median OS months in the TLGPERCIST 4411.90 group was inaccessible, the median OS in the 4411.90 group was 32.00 95CI: 0.00-87.43 months. Median OS months was statistically significant in MTV41 groups p0.047. While median OS months was inaccessible in the MTV41376.10 group, median OS in the 376.10 group was 32.00 95CI: 0.00-87.43 months. Conclusion: The MTV41 and TLGPERCIST appear to be the best parameter to predict OS in patients diagnosed with DLBCL by 18F-FDG PETCT.

 Aims: 18F-fluorodeoxyglucose 18F-FDG positron emission tomographycomputed tomography PETCT, plays an important role in both staging at the time of diagnosis and follow-up of treatment response in lymphoma. Our aim was to investigate the effect of different quantitative metabolic parameters, which are not used in routine practice, on treatment response and overall survival OS in patients with diffuse large B-cell lymphoma. Methods: A total of 26 patients were included in our retrospective cohort study. Deauville 5-point scale 5-PS, and cut-off values for changes in maximum standardized uptake value SUVmax, peak SUV SUVpeak, metabolic tumor volume MTV2.5-41- PERCIST -aort and total lesion glycolysis index TLG 2.5-41- PERCIST-aort effect of metabolic parameters on treatment response and OS was investigated. Results: Metabolic parameters did not predict treatment response, while TLGPERCIST p0.034, TLGAORT p0.040, MTV41 p0.040 and TLG41 p0.034 parameters were statistically significant for OS. Median OS months was statistically significant in TLGPERCIST groups p0.047. While the median OS months in the TLGPERCIST 4411.90 group was inaccessible, the median OS in the 4411.90 group was 32.00 95CI: 0.00-87.43 months. Median OS months was statistically significant in MTV41 groups p0.047. While median OS months was inaccessible in the MTV41376.10 group, median OS in the 376.10 group was 32.00 95CI: 0.00-87.43 months. Conclusion: The MTV41 and TLGPERCIST appear to be the best parameter to predict OS in patients diagnosed with DLBCL by 18F-FDG PETCT.

 Aims: 18F-fluorodeoxyglucose 18F-FDG positron emission tomographycomputed tomography PETCT, plays an important role in both staging at the time of diagnosis and follow-up of treatment response in lymphoma. Our aim was to investigate the effect of different quantitative metabolic parameters, which are not used in routine practice, on treatment response and overall survival OS in patients with diffuse large B-cell lymphoma. Methods: A total of 26 patients were included in our retrospective cohort study. Deauville 5-point scale 5-PS, and cut-off values for changes in maximum standardized uptake value SUVmax, peak SUV SUVpeak, metabolic tumor volume MTV2.5-41- PERCIST -aort and total lesion glycolysis index TLG 2.5-41- PERCIST-aort effect of metabolic parameters on treatment response and OS was investigated. Results: Metabolic parameters did not predict treatment response, while TLGPERCIST p0.034, TLGAORT p0.040, MTV41 p0.040 and TLG41 p0.034 parameters were statistically significant for OS. Median OS months was statistically significant in TLGPERCIST groups p0.047. While the median OS months in the TLGPERCIST 4411.90 group was inaccessible, the median OS in the 4411.90 group was 32.00 95CI: 0.00-87.43 months. Median OS months was statistically significant in MTV41 groups p0.047. While median OS months was inaccessible in the MTV41376.10 group, median OS in the 376.10 group was 32.00 95CI: 0.00-87.43 months. Conclusion: The MTV41 and TLGPERCIST appear to be the best parameter to predict OS in patients diagnosed with DLBCL by 18F-FDG PETCT.

Makale detayları

The effect of 18F-FDG PET/CT findings on prognosis in patients with diffuse large B cell lymphoma

Yazarlar:

Seda Yılmaz | Mustafa Erol

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Hematoloji

Dergi:

Journal of Health Sciences and Medicine Vol.6 Issue 6, pp.1337-1341

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001303060

pISSN:

2636-8579

Diffuse large cell lymphoma

Metabolic tumor volume

Overall survival

PET Response

Total lesion glycolysis

Sayı

Makale detayları

The effect of 18F-FDG PET/CT findings on prognosis in patients with diffuse large B cell lymphoma

Yazarlar: Seda Yılmaz | Mustafa Erol

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Hematoloji

Dergi: Journal of Health Sciences and Medicine Vol.6 Issue 6, pp.1337-1341

Belge Tipi: Makale

Yayın Tarihi: 10/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001303060

pISSN: 2636-8579

Diffuse large cell lymphoma

Metabolic tumor volume

Overall survival

PET Response

Total lesion glycolysis

Sayı

Yazarlar:

Seda Yılmaz | Mustafa Erol

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Hematoloji

Dergi:

Journal of Health Sciences and Medicine Vol.6 Issue 6, pp.1337-1341

Belge Tipi:

Makale

Yayın Tarihi:

10/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001303060

pISSN:

2636-8579